NCT01595295

Registry on Hypomethylating Agents in Myeloid Neoplasms

Registry on Hypomethylating Agents in Myeloid Neoplasms, Including Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) and Acute Myeloid Leukemia (AML)

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 1,500 (actual)
• Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This registry is set up to collect real-world experience in the management of patients with myeloid neoplasms, in particularly in patients with MDS, CMML or AML, treated with hypomethylating agents in Austria and potentially other participating countries. This registry will collect data in a retrospective as well as in a prospective manner at various sites. The aim is to gain valuable insights on both efficacy and toxicity of these drugs in a routine clinical setting in patients with various comorbidities.

Conditions

• Chronic Myelomonocytic Leukemia
• Myelodysplastic Syndromes
• Acute Myeloid Leukemia

Interventions

Type	Name	Description
OTHER	non interventional

Timeline

• Start date: 2009-02-09
• Primary completion: 2021-12-31
• Completion: 2021-12-31
• First posted: 2012-05-10
• Last updated: 2024-03-25

Locations

20 sites across 2 countries: Austria, Croatia